

DESCRIPTION

TSA305 GENE

TECHNICAL FIELD

The present invention relates to a gene, named
5 TSA305, coding for a protein specifically expressed in the
pancreas and, more particularly, to the above pancreas-
specific gene having a high level of homology with
nematode sel-1 and expected to show an anticancer activity.
The invention also relates to a novel protein encoded by
10 such gene and to a specific antibody thereto.

BACKGROUND ART

Pancreatic cancer holds the fourth and fifth place
on the list of cancer-related deaths in Japan and western
countries, respectively and has the worst prognosis among
15 digestive system malignancies (Poston, J. G., et al., Gut,
32, 800-812 (1991)). The ultimate goal in cancer research
is to discriminate early stage gene changes leading to
malignant transformation. If such changes can be
differentiated, genetic tools for early diagnosis may
20 possibly be developed and novel therapeutic approaches for
more effective treatment of this lethal disease will
possibly be taken.

Meanwhile, the nematode sel-1 gene reportedly has an
inhibitory action on Notch/lin-12 which suppresses the
25 differentiation of ectoderm into neuroblast in neural

development in nematodes (Genetics, 143 (1), 237-247
(1996); Development, 124 (3), 637-644 (1997)). Said
Notch/lin-12, when forcedly expressed, causes breast
cancer or leukemia and therefore is considered to be a
5 cancer-related gene. The above sel-1 gene suppressively
acting on said cancer-related gene is therefore considered
to suppressively act on cancer as well. At present,
however, the roles of these genes have not been fully
elucidated.

10 Elucidation of the physiological roles of such genes
and the information obtained therefrom are important in
elucidating the mechanisms of onset of diseases such as
malignant transformation and inflammation and are desired
not only in the field of basic scientific studies but also
15 in the pharmaceutical field in determining the causes of
such diseases as cancer and inflammation and developing
treatment methods for such diseases.

DISCLOSURE OF INVENTION

The present invention has for its object to provide
20 the above information desired in the relevant field of art,
in particular a gene coding for a novel protein homolog
and having homology with the sel-1 gene.

With that object in view, the present inventors made
an arduous search among genes derived from various human
25 tissues and, as a result, succeeded in newly isolating and

identifying a gene coding for a protein specifically expressed in the pancreas and found that the above object can be realized with said gene. As a result, the present invention has now been completed.

5 Thus, the present invention provides a pancreas-specific gene, TSA305, comprising a nucleotide sequence coding for a protein having the amino acid sequence shown under SEQ ID NO:1, in particular the TSA305 gene which is a human gene.

10 The invention also provides a pancreas-specific protein (TSA305 protein) comprising the amino acid sequence shown under SEQ ID NO:1 and an antibody capable of coupling therewith.

 The invention further provides a pancreas-specific
15 gene, TSA305, which is a polynucleotide defined below under (a) or (b) in particular to the TSA305 gene which is a human gene:

(a) A polynucleotide comprising the whole or part of the nucleotide sequence shown under SEQ ID NO:2.

20 (b) A polynucleotide capable of hybridizing with a DNA having the nucleotide sequence shown under SEQ ID NO:2 under stringent conditions.

 In addition, the present invention provides the above gene in DNA fragment form which is useful as a
25 specific probe or specific primer for gene detection.

In expressing amino acids, peptides, nucleotide sequences, nucleic acids and the like by abbreviations or symbols in the following, the nomenclature of the IUPAC-IUB [IUPAC-IUB Communication on Biological Nomenclature, Eur. J. Biochem., 138: 9 (1984)], the "Guideline for preparing specifications etc. containing nucleotide sequences or amino acid sequences" (edited by the Patent Office of Japan) and the conventional symbols in the relevant field are followed or used.

10 As a specific example of the gene of the invention, there may be mentioned the one deduced from the DNA sequence of a PCR product named "TSA305" which is to be shown later in the example section. The nucleotide sequence thereof is as shown under SEQ ID NO:3.

15 Said gene is a human cDNA containing a coding region having the nucleotide sequence shown under SEQ ID NO:2 and coding for a novel pancreas-specific protein (hereinafter referred to as TSA305 protein) composed of 794 amino acid residues as shown under SEQ ID NO:1 and is composed of a
20 total length of 7,885 nucleotides.

 As a result of searching in the GenBank/EMBL database utilizing the FASTA program (Person, W. R., et al., Proc. Natl. Acad. Sci. USA, 85, 2444-2448 (1988)), it was confirmed that the product of expression of the TSA305
25 gene of the invention, namely the TSA305 protein, has a

very high level of homology with the nematode sel-1 gene (cf. the reference cited above). In view of this fact, it is considered that the gene of the invention, like the above-mentioned sel-1, act suppressively on Notch/lin-12
5 which is a cancer-related gene considered to be involved in embryogenesis in general.

The locus of the gene of the invention is q24.3-q31.1 of the 14th chromosome where a gene causative of insulin-dependent diabetes mellitus (IDDM) is considered
10 to exist. In view of this fact, it is strongly suggested that the gene of the invention be related with diabetes.

It was further revealed that the product of expression of the gene of the invention is a protein containing a fibronectin type II collagen binding domain.
15 Such collagen binding site close to the N terminal suggests involvement of the protein in fibrogenesis and, based on this, it is strongly suggested that the gene of the invention be involved in fibrosis.

In addition, since all of the pancreatic carcinoma
20 preparations tested showed a failure of expression of the gene of the invention and the gene is expressed mainly in normal pancreases, it is suggested that the gene of the invention be potentially valuable in forecasting malignant transformation.

25 Thus, information and means very useful in

elucidating, understanding, diagnosing, preventing and
treating various diseases such as mammary cancer, leukemia,
fibrosis, diabetes and pancreatic carcinoma, in particular
pancreatic carcinoma, are given as a result of providing
5 the TSA305 gene and the product of its expression
according to the present invention. The gene of the
invention can judiciously be used also in developing a
novel drug inducing the expression of the gene of the
invention which is utilizable in the treatment of various
10 diseases such as mentioned above. Furthermore, detection
of the expression of the gene of the invention or the
product of its expression in an individual animal or a
specific tissue or detection of a mutation (deletion or
point mutation) of said gene or abnormal expression
15 thereof, for instance, is considered to be utilizable
adequately in elucidating or diagnosing the above diseases.

The gene of the invention is specifically
represented by a gene containing a nucleotide sequence
coding for a protein having the amino acid sequence shown
20 under SEQ ID NO:1 or a gene which is a polynucleotide
containing the nucleotide sequence shown under SEQ ID NO:2.
However, the gene of the invention is not particularly
limited to these but may be, for example, a gene leading
to a certain modification in the above specific amino acid
25 sequence or a gene having a certain level of homology with

the above specific nucleotide sequence.

Thus, the gene of the invention also includes a gene containing a nucleotide sequence coding for a protein having an amino acid sequence derived from the amino acid sequence shown under SEQ ID NO:1 by deletion, substitution or addition of one or a plurality of amino acid residues and having the same activity as that of TSA305. The extent and site(s) of "deletion, substitution or addition of an amino acid residue or residues" are not particularly restricted if the modified protein is a product of the same effect which has the same function as the protein having the amino acid sequence shown under SEQ ID NO:1. The term "plurality" used above means 2 or more, normally several.

While the modification (mutation) or the like of the above amino acid sequence may occur naturally, for example by mutation or posttranslational modification, artificial modification is also possible based on a nature-derived gene (for example, a specific example of the gene of the present invention). The present invention covers all modified genes having the above characteristic without reference to the cause and means, among others, of such modification or mutation.

As examples of the above artificial means, there may be mentioned site-specific mutagenesis [Methods in

Enzymology, 154: 350, 367-382 (1987; ibid., 100: 468
(1983); Nucleic Acids Res., 12: 9441 (1984); Zoku
Seikagaku Jikken Koza (Experiments in Biochemistry, second
series) 1: "Idensi Kenkyuho (Methods in Gene Research) II",
5 edited by the Biochemical Society of Japan, p. 105 (1986)]
and other genetic engineering techniques, means of
chemical synthesis such as the phosphotriester method or
phosphoamidite method [J. Am. Chem. Soc., 89: 4801 (1967);
ibid., 91: 3350 (1969); Science, 150: 178 (1968);
10 Tetrahedron Lett., 22: 1859 (1981); ibid., 24: 245 (1983)],
and combinations thereof.

In a mode of embodiment of the gene of the present
invention, there may be mentioned a gene which is a
polynucleotide containing the whole or part of the
15 nucleotide sequence shown under SEQ ID NO:3. The open
reading frame (nucleotide sequence shown under SEQ ID
NO:2) containing in this nucleotide sequence also serves
as an example of combination of codons specifying
respective amino acid residues in the above amino acid
20 sequence (SEQ ID NO:1). The gene of the invention is not
limited to this but can of course have a nucleotide
sequence in which an arbitrary combination of codons is
selected. The selection of codons can be made in the
conventional manner, for example the codon usage in the
25 host employed, among others, can be taken into

consideration [Nucleic Acids Res., 9: 43 (1981)].

While the gene of the invention is represented in terms of single strand DNA nucleotide sequence, as shown, for example, under SEQ ID NO:2, the invention of course
5 includes a polynucleotide having a nucleotide sequence complementary to such nucleotide sequence, or a component comprising both of these as well. It is not limited to a DNA such as a cDNA.

Furthermore, as mentioned above, the gene of the
10 invention is not limited to a polynucleotide containing the whole or part of the nucleotide sequence shown under SEQ ID NO:2, but includes genes comprising a nucleotide sequence having a certain level of homology with said nucleotide sequence as well. As such genes, there may be
15 mentioned those at least capable of hybridizing with a DNA comprising the nucleotide sequence shown under SEQ ID NO:2 under such stringent conditions as mentioned below and incapable of being released therefrom even by washing under certain conditions.

20 Thus, mention may be made, as an example, of a gene having a nucleotide sequence which hybridizes with a DNA having the nucleotide sequence shown under SEQ ID NO:2 under conditions: at 65°C overnight in 6 × SSC or at 37°C overnight in 4 × SSC containing 50% formamide and is not
25 released from said DNA under washing conditions: 30

minutes at 65°C with 2 × SSC. Here, "SSC" means standard saline citrate; 1 × SSC = 0.15 M NaCl, 0.015 M sodium citrate).

The gene of the present invention can be produced
5 and recovered with ease by general genetic engineering techniques [see, for example, Molecular Cloning, 2nd Ed., Cold Spring Harbor Lab. Press (1989); Zoku Seikagaku Jikken Koza (Experiments in Biochemistry, second series) "Idensi Kenkyuho (Methods in Gene Research) I, II and III",
10 edited by the Biochemical Society of Japan (1986)] based on the information on the sequence of a typical example thereof.

Specifically, the production/recovery can be carried out by constructing a cDNA library in the conventional
15 manner from an appropriate origin in which the gene of the invention is expressed and selecting a desired clone therefrom using an appropriate probe or antibody specific to the gene of the invention [Proc. Natl. Acad. Sci. USA, 78: 6613 (1981); Science, 222: 778 (1983)].

20 As examples of the origin of cDNA in the above process, there may be mentioned various cells and tissues in which the gene of the invention is expressed, cultured cells derived therefrom and the like, in particular the pancreatic tissue. Isolation of total RNA from these,
25 isolation and purification of mRNA, obtainment of cDNA and

cloning thereof, among others, can all be performed in the conventional manner. cDNA libraries are also commercially available and such cDNA libraries, for example various cDNA libraries commercially available from Clontech Lab.

5 Inc. can also be used in the practice of the present invention.

The method of screening the cDNA library for the gene of the invention is not particularly restricted but may be a conventional one. As specific examples, there
10 may be mentioned the method comprising selecting the corresponding cDNA clone by immunological screening using a specific antibody to the protein produced by the cDNA, plaque hybridization or colony hybridization using a probe selectively binding to the desired DNA sequence, and
15 combinations of these.

As examples of the probe to be used here, there may generally be mentioned DNAs chemically synthesized based on the information on the nucleotide sequence of the gene of the invention, among others. Of course, it is also
20 possible to successfully utilize the gene of the invention already obtained as such or fragments thereof.

The screening for the gene of the invention can also be made by the protein interaction cloning procedure using the TSA305 protein in lieu of the above specific antibody
25 and, further, the screening method comprising using, as a

screening probe, a sense or antisense primer designed based on the information on the nucleotide sequence of the gene of the invention can also be employed.

In accordance with the present invention, the mRNA
5 expression levels in cells under different conditions or a plurality of different cell groups can be directly compared and investigated by the differential display technique (Liand, P., et al., Science, 257: 967-971 (1992)).

10 In obtaining the gene of the present invention, DNA/RNA amplification by the PCR technique [Science, 230: 1350 (1985)] can judiciously be utilized. In particular, in cases where it is difficult to obtain the full-length cDNA from a library, the RACE technique (rapid
15 amplification of cDNA ends; Jikken Igaku (Experimental Medicine), 12 (6): 35 (1994)), in particular the 5'-RACE technique [Proc. Natl. Acad. Sci. USA, 85: 8998 (1988)], for instance, is judiciously employed. The primers to be used when such PCR technique is employed can be adequately
20 designed based on the information on the sequence of the gene of the invention as revealed by the present invention and can be synthesized in the conventional manner.

The amplified DNA/RNA fragments can be isolated and purified in the conventional manner, as mentioned above,
25 for example by gel electrophoresis.

The gene of the invention or various DNA fragments obtained in the above manner can be sequenced in the conventional manner, for example by the dideoxy method [Proc. Natl. Acad. Sci. USA, 74: 5463 (1977)] or the
5 Maxam-Gilbert method [Methods in Enzymology, 65: 499 (1980)] or, in a simple and easy manner, by using a commercial sequencing kit or the like.

By utilizing the gene of the present invention, it is possible to readily produce the corresponding gene
10 product stably in large amounts by using general genetic engineering techniques. Therefore, the present invention also provides a vector (expression vector) containing the TSA305 gene of the invention, host cells transformed with said vector and a method of producing the TSA305 protein
15 which comprises cultivating said host cells.

The production method can be carried out according to the ordinary recombinant DNA technology [see, for example, Science, 224: 1431 (1984); Biochem. Biophys. Res. Comm., 130: 692 (1985); Proc. Natl. Acad. Sci. USA, 80:
20 5990 (1983); and the references cited above].

Both prokaryotes and eukaryotes can be used as the host cells mentioned above. As prokaryotic hosts, there may be mentioned a wide variety of ones in general use, such as Escherichia coli, Bacillus subtilis, etc., and
25 preferred examples are those included among Escherichia

coli strains, in particular the Escherichia coli K 12 strain. The eukaryotic host cells include vertebrate cells and yeast cells, among others. As the former, COS cells [Cell, 23: 175 (1981)], which are simian cells, 5 chinese hamster ovary cells and the dihydrofolate reductase-deficient strain thereof [Proc. Natl. Acad. Sci. USA, 77: 4216 (1980)], for instance, are judiciously used and, as the latter, yeast cells belonging to the genus Saccharomyces and the like are judiciously used. Of 10 course, the host cells are not limited to these.

Where prokaryotic cells are used as the host, an expression plasmid can judiciously be used which is constructed using a vector capable of replicating in said host cells and providing this vector with a promoter and 15 the SD (Shine and Dalgarno) sequence upstream of the gene of the invention and further with an initiation codon (e.g. ATG) necessary for the initiation of protein synthesis so that the gene of the invention may be expressed. Often used as the above vector are generally Escherichia coli- 20 derived plasmids, for example pBR322, pBR325, pUC12 and pUC13. The vector is not limited to these, however, but various known vectors may be utilized. As commercially available vectors of the above kind which can be used in expression systems in which Escherichia coli is used, 25 there may be mentioned, for example, pGEX-4T (Amersham

Pharmacia Biotech), pMAL-C2, pMAL-P2 (New Englands Biolabs), pET21, pET21/lacq (Invitrogen) and pBAD/His (Invitrogen).

As the expression vector in the case of vertebrate cells being used as the host, there may be mentioned one
5 generally having a promoter located upstream of the gene of the invention which is to be expressed, an RNA splicing site, a polyadenylation site and transcription termination sequence. When necessary, this may further have an origin of replication. As specific examples of said expression
10 vector, there may be mentioned pSV2dhfr having the early promoter of SV40 [Mol. Cell. Biol., 1: 854 (1981)] and the like. In addition to the above, various known commercial vectors can also be used. As commercial vectors of such kind which are to be utilized in expression systems in
15 which animal cells are used, there may be mentioned, among others, vectors for animal cells, such as pEGFP-N, pEGFP-C (Clontech), pIND (Invitrogen) and pcDNA3.1/His (Invitrogen), and vectors for insect cells, such as pFastBac HT (Gibco BRL), pAcGHLT (PharMingen), pAc5/V5-His, pMT/V5-His and pMT/Bip/V5-His (the latter three:
20 Invitrogen).

As specific examples of the expression vector to be used when yeast cells are used as the host, there may be mentioned, among others, pAM82 having a promoter for the
25 acid phosphatase gene [Proc. Natl. Acad. Sci. USA, 80; 1

(1983)] and the like. Commercial expression vectors for yeast cells include, among others, pPICZ (Invitrogen) and pPICZ α (Invitrogen).

The promoter is not particularly restricted, either.

5 When an Escherichia species is used as the host, the tryptophan (trp) promoter, lpp promoter, lac promoter, recA promoter, PL/PR promoter or the like can judiciously be utilized. When the host is a Bacillus species, the SP01 promoter, SP02 promoter, penP promoter or the like is
10 preferred. As for the promoter to be used when a yeast species is the host, the pH05 promoter, PGK promoter, GAP promoter or ADH promoter, for instance, can judiciously be used. As preferred examples of the promoter to be used when animal cells are used as the host, there may be
15 mentioned SV40-derived promoters, retrovirus promoters, and the metallothionein promoter, heat shock promoter, cytomegalovirus promoter and SR α promoter.

Conventional fused protein expression vectors can also judiciously be used as the expression vector for the
20 gene of the present invention. As specific examples of such vectors, there may be mentioned pGEX (Promega) for the expression of a protein fused with glutathione-S-transferase (GST) and the like.

The method of introducing the desired recombinant
25 DNA (expression vector) into host cells for transforming

the same is not particularly restricted, either, but various general methods can be employed. The transformant obtained can be cultivated in the conventional manner, whereby the desired TSA305 protein encoded by the gene of
5 the present invention is expressed/produced and accumulated or secreted within or outside the transformant cells or on the cell membrane.

The medium to be used in the above cultivation can adequately be selected from among various conventional
10 ones according to the host cells employed, and the cultivation can be conducted under conditions suited for the growth of the host cells.

The thus-obtained recombinant protein (TSA305 protein) can be isolated and purified, as desired, by
15 various separation procedures utilizing its physical and/or chemical properties, among others [see, for example, "Seikagaku (Biochemical) Data Book II", pages 1175-1259, 1st edition, 1st printing, published June 23, 1980 by Tokyo Kagaku Dojin; Biochemistry, 25 (25); 8274 (1986);
20 and Eur. J. Biochem., 163: 313 (1987)]. As said methods, there may specifically be mentioned, for example, ordinary reconstitution treatment, treatment with a protein precipitating agent (salting out), centrifugation, osmotic shock procedure, sonication, ultrafiltration, various
25 chromatographic techniques such as molecular sieve

chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography and high-performance liquid chromatography (HPLC), dialysis and combinations of these. Particularly preferred among
5 the above methods is affinity chromatography using a column to which a specific antibody to the TSA305 protein of the invention is bound.

Thus, the present invention further provides the novel TSA305 protein itself as obtained, for example, in
10 the above manner. As mentioned hereinabove, said protein has a high level of homology with the nematode sel-1 and can produce an inhibitory effect on various kinds of cancer and therefore useful in the pharmaceutical field.

This TSA305 protein can also be utilized as an
15 immunogen for producing an antibody specific to said protein. The component to be used here as the antigen may be the protein mass-produced by the genetic engineering techniques mentioned above or a fragment thereof, for instance. By utilizing such antigen, it is possible to
20 obtain the desired antiserum (polyclonal antibody) or monoclonal antibody. The methods of producing said antibody are themselves well known to those skilled in the art and, in the practice of the present invention as well, these conventional methods can be followed [see, for
25 example, Zoku Seikagaku Jikken Koza (Experiments in

Biochemistry, second series) "Men-eki Seikagaku kenkyuho (Methods in Immunobiochemistry)", edited by the Biochemical Society of Japan (1986)].

Thus, for example, the animal to be immunized for
5 obtaining antisera can be arbitrarily selected from among ordinary animals such as rabbits, guinea pigs, rats, mice and chickens, and immunization with the antigen mentioned above, blood collection and other procedures can also be carried out in the conventional manner.

10 The monoclonal antibody, too, can be produced in the conventional manner by producing hybrid cells from plasmocytes (immunocytes) of an animal immunized with the immunogen mentioned above and plasmacytoma cells, selecting a desired antibody-producing clone from among
15 them, and cultivating said clone. The animal to be immunized is generally selected taking into consideration the compatibility with the plasmacytoma cells employed for cell fusion and, generally, mice or rats, among others, are advantageously used. The immunization can be
20 conducted in the same manner as in the above-mentioned case of antisera and, if desirable, an ordinary adjuvant or the like may be used in combination.

The plasmacytoma cells to be used for cell fusion are not particularly restricted but, for example, various
25 myeloma cells such as p3 (p3/x63-Ag8) [Nature, 256: 495-

497 (1975)], p3-U1 [Current Topics in Microbiology and Immunology, 81: 1-7 (1978)], NS-1 [Eur. J. Immunol., 6: 511-519 (1976)], MPC-11 [Cell, 8: 405-415 (1976)], SP2/0 [Nature, 276: 269-271 (1978) and the like, R210 in rats
5 [Nature, 277: 131-133 (1979)] and the like as well as cells derived therefrom all can be used.

The fusion of the above immunocytes and plasmacytoma cells can be performed by a known method in the presence of a conventional fusion accelerator such as polyethylene
10 glycol (PEG) or Sendai virus (HVJ) and the desired hybridomas can also be isolated in the conventional manner [e.g. Meth. in Enzymol., 73: 3 (1981); Zoku Seikagaku Jikken Koza (Experiments in Biochemistry, second series) cited above].

15 The desired antibody-producing cell line can be searched for and a monoclonal antibody can be derived therefrom in the conventional manner. Thus, for example, the search for an antibody-producing cell line can be carried out using the above-mentioned antigen of the
20 present invention by various methods generally used in detecting antibodies, such as the ELISA technique [Meth. in Enzymol., 70: 419-439 (1980)], plaque technique, spot technique, agglutination reaction technique, Ouchterlony technique, and radioimmunoassay.

25 The antibody of the invention can be collected from

the thus-obtained hybridomas, for example, by cultivating said hybridomas in the conventional manner and collecting the culture supernatant or by administering the hybridomas to an mammal compatible therewith and, after hybridoma
5 growth, collecting the ascitic fluid. The former method is suited for obtaining a high-purity antibody while the latter method is suited for mass production of an antibody. The thus-obtained antibody can further be purified by conventional means such as salting out, gel filtration and
10 affinity chromatography.

The thus-obtained antibody is characterized by its ability to bind to the TSA305 protein of the invention and can advantageously be utilized in the above-mentioned purification of the TSA305 protein and in assaying or
15 discriminating the same by immunological techniques. The present invention thus provides such novel antibody as well.

Further, based on the information on the sequence of the gene of the invention as revealed by the present
20 invention, the expression of the gene of the invention in individuals or in various tissues can be detected, for example by utilizing the whole or part of the nucleotide sequence of said gene.

Such detection can be carried out in the
25 conventional manner, for example by RNA amplification by

RT-PCR [reverse transcribed polymerase chain reaction; E. S. Kawasaki et al., Amplification of RNA. In PCR Protocol, A Guide to methods and applications, Academic Press, Inc., San Diego, 21-27 (1991)], northern blot analysis

5 [Molecular Cloning, Cold Spring Harbor Lab. (1989)], in situ RT-PCR [Nucl. Acids Res., 21: 3159-3166 (1993)], in situ hybridization or a like technique for assaying the same on the cellular level or by the NASBA technique [nucleic acid sequence-based amplification; Nature, 350:

10 91-92 (1991)] or other various techniques. All can give good results.

When the RT-PCR technique is employed, the primers to be used are not limited in any way provided that they are specific to the gene of the invention and enable

15 specific amplification of said gene alone. The sequences thereof can be adequately designed based on the genetic information according to the present invention. Generally, each may have a partial sequence comprising about 20 to 30 nucleotides.

20 In this way, the present invention provides DNA fragments useful as specific primers and/or specific probes in detecting the TSA305 gene according to the invention as well.

BRIEF DESCRIPTION OF DRAWINGS

25 Fig. 1 is a photograph, in lieu of a drawing,

illustrating the distribution of the gene of the invention in human tissues as examined by the northern blot analysis described in Example 1 under (2).

Fig. 2 is a photograph, in lieu of a drawing,
5 illustrating the results of RT-PCR analysis of normal pancreatic cells and four cell lines as obtained in Example 1 (4). The results for TSA305 are shown in the upper section and the results for β_2 -microglobulin as a control are shown in the lower section.

10 Fig. 3 is a photograph, in lieu of a drawing, illustrating the results of RT-PCR analysis of pancreatic carcinoma samples and others as obtained in Example 1 (5). The results for TSA305 are shown in the upper section and the results for β_2 -microglobulin as a control are shown in
15 the lower section.

BEST MODE FOR CARRYING OUT THE INVENTION

The following examples are given for illustrating the present invention in more detail.

Example 1

20 (1-1) Method of manifestation by labeling with [α - 33 P]ATP

For identifying the human gene expressed in a tissue-specific process, the method of manifestation by labeling with [α - 33 P]ATP was used. The procedure of said method was followed essentially according to the method of
25 Liang (Liang, P., et al., Science, 257: 967-971 (1992)),

as mentioned below.

Thus, polyA RNA (0.2 µg) isolated from each of 13 human tissues (adult brain, fetal brain, lung, liver, stomach, pancreas, spleen, mammary gland, bladder, placenta, testis, kidney and heart; products of Clontech) was mixed with 25 pmol of 3'-anchored oligo-dT primer G(T)15MA (M being a mixture of G, A and C) in 8 µl of diethyl pyrocarbonate-treated water and the mixture was heated at 65°C for 5 minutes. To this solution were added 4 µl of 5 × First strand buffer (product of BRL), 2 µl of 0.1 M DTT (product of BRL), 1 µl of 250 mM dNTPs (product of BRL), 1 µl of ribonuclease inhibitor (40 units; product of Toyobo) and 1 µl of SuperScript II reverse transcriptase (200 units; product of BRL). The final volume of each reaction mixture was 20 µl. Each solution was incubated at 37°C for 1 hour and then 2.5-fold diluted by addition of 30 µl of distilled water and the dilution was stored at -20°C until the time of use.

cDNA was amplified by PCR in the presence of [α -³³P]ATP-labeled (product of Amersham) 3'-anchored primer. This cDNA amplification by PCR was conducted in the following manner. Thus, 20 µl of each PCR mixture contained 2 µl of RT reaction mixture, 2 µl of 10 × PCR buffer (product of Takara), 4 µl of 2.5 mM dNTPs, 0.25 µl of ExTaq DNA polymerase (5 units/ml; product of Takara),

25 pmol of [α -³³P]ATP-labeled 3'-anchored oligo-dT primer and 25 pmol of 5'-primer (No. 20, decamer deoxyoligo-nucleotide primer having an arbitrary sequence, in this case the nucleotide sequence shown under SEQ ID NO:4).

5 The PCR reaction was carried out under the following conditions. Thus, one cycle was conducted at 95°C for 3 minutes, at 40°C for 5 minutes and at 72°C for 5 minutes, then 40 cycles were conducted each at 95°C for 0.5 minutes, at 40°C for 2 minutes and at 72°C for 1 minute and,
10 finally, the reaction was allowed to proceed at 72°C for 5 minutes.

Each PCR reaction sample was extracted with ethanol and resuspended in formamide-sequencing dye and the reaction was allowed to proceed on a 6% acrylamide-7.5 M
15 ureas sequencing gel. The gel was dried without fixation and autoradiography was carried out overnight.

(1-2) Subcloning of the amplified cDNA fragment

3MM filter paper with the dried gel placed thereon was marked with radioactive ink in advance. By checking
20 the autoradiogram against this mark, the gel containing the desired cDNA-containing band was excised together with the 3MM filter paper and stirred with 300 μ l of dH₂O for 1 hour. After removal of the polyacrylamide gel and filter paper, the cDNA was rerecovered by ethanol precipitation
25 in the presence of 1 μ l of 10 mg/ml glycogen and 0.3 M

NaOAc as a carrier and redissolved in 10 μ l of dH₂O. For reamplification, 5 μ l of this solution was used. The PCR conditions and primers were the same as those in the first PCR. The reamplification product having an appropriate
5 size was recovered as the first PCR product, and the PCR product was then cloned into the pUC118 vector (product of Takara) at the HincII site. The nucleotide sequence was determined using an ABI 377 automated sequencer (product of Applied Biosystems).

10 The different patterns manifested upon use of the mRNAs isolated from the 13 human tissues were compared and, as a result, a PCR product specifically expressed in pancreas was identified. This was named TSA305.

 This product was composed of 371 nucleotides.

15 Comparison of the data on this nucleotide with the DNA sequences occurring in the GenBank/EMBL data base using the FASTA program (Person, W. R., et al., Proc. Natl. Acad. Sci. USA, 85: 2444-2448 (1988)) revealed that this PCR
20 product has no homology with any of other known DNA sequences.

(1-3) cDNA screening

 A human normal pancreas cDNA library was constructed using oligo(dT) + random hexamer-primed human normal pancreas cDNA and Uni-ZAPTM XR (product of Stratagene).

25 The total of 1×10^6 clones were isolated by the method

mentioned above and subjected to screening using a [α -³³P]-dCTP-labeled cDNA fragment. Positive clones were selected and the insert cDNA portions thereof were excised in vivo in pBluescript II SK(-).

5 As a result, about 100 plaques were identified as corresponding to TSA305. Based on this result, the percent transcription among all RNAs was calculated to be about 0.01%. The assembled cDNA sequence (TSA305) homologous with TSA305 comprises 7,885 nucleotides
10 containing an open reading frame of 2,382 nucleotides coding for a protein composed of 794 amino acid residues with a calculated molecular weight of 88,768 Da.

 Based on the primary sequence, it was revealed that this gene product (TSA305 protein) is a protein containing
15 a fibronectin type II collagen binding domain.

 The locus thereof was found to be q24.3-q31.1 on the 14th chromosome where a gene causative of insulin-dependent diabetes mellitus (IDDM) is considered to exist.

 The TSA305 gene of the present invention showed a
20 high level of homology with the nematode sel-1.

(2) Expression in tissues

 For checking the expression profiles of TSA305 in tissues, northern blot analysis was carried out using various human tissues.

25 For the northern blot analysis, human MTN (Multiple

Tissue Northern) blots I and II (products of Clontech) were used. The cDNA fragments were labeled with [α -³³P]-dCTP by PCR using a set of primers with T3 and T7 promoter sequences. The amplification product-containing membrane
5 was prehybridized (the conditions were as indicated in the product protocol), followed by hybridization according to the product protocol.

After hybridization, the membrane was washed and exposed to an autoradiograph at -80°C for 24 hours. The
10 results are shown in Fig. 1.

In the figure, the human tissues used were heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocytes.

15 In the figure, a transcript homologous with TSA305 was observed specifically in the pancreas.

(3) FISH

FISH was carried out for chromosome arrangement according to a known method (Takahashi, E., et al., Hum. Genet., 86: 14-16 (1990)) using 0.5 µg of each cosmid DNA
20 as a probe. FISH was detected with a Provia 100 film (product of Fuji, ISO 100) or a CCD camera system (Applied Imaging, product of Sightvision).

As a result, the signals obtained by testing 100
25 typical cells at (pro)metaphase by R banding were found

localized on the bands q24.3-q31.1 of the 14th chromosome. Therefore, the locus of localization of the TSA305 on the chromosome could be identified as 14q24.3-q31.1.

(4) Expression of transcript in pancreatic carcinoma cell lines and in pancreatic carcinoma tissues as revealed by RT-PCR analysis

To check whether the expression of the TSA305 gene varies in human pancreatic carcinoma cell lines and pancreatic carcinoma tissues, four cell lines (Aspc1 (metastatic adenocarcinoma; J. Natl. Cancer Inst., 67: 563-569 (1981)), Bxpc3 (adenocarcinoma, undifferentiated; Cancer Invest., 4: 15-23 (1986)), MiaPaca2 (adenocarcinoma; Int. J. Cancer, 19: 128-135 (1977)) and PANC1 (epithelioid, pancreatic duct carcinoma; Int. J. Cancer, 15: 741-747 (1975)) and 9 pancreatic carcinoma tissues (gifts from Dr. Nakamura at the University of Tokyo Institute of Medical Sciences) were subjected to RT-PCR analysis.

Thus, 10 µl of the total RNA isolated from each cell line or pancreatic carcinoma tissue using ISOGEN (product of Wako) was treated with 10 units of RNase-free DNase I (product of Boehringer Mannheim) for 15 minutes, followed by two repetitions of extraction with phenol-chloroform and precipitation with ethanol. The single-stranded cDNA was synthesized using Superscript ITM RNase H reverse

transcriptase (product of Life Technology) with oligo-d(T) and random primers. A 2- μ l portion of each product was used for PCR amplification.

The primers P1 and P2S having the nucleotide
5 sequences shown under SEQ ID NO:5 and SEQ ID NO:6,
respectively, were used in 25 cycles of PCR amplification.

The PCR reaction was carried out in 20 μ l of a
solution containing 25 ng of cDNA, 10 μ M each primer, 2.5
mM dNTP and 0.25 U of Extaq DNA polymerase (product of
10 Takara). Each PCR product was dissolved in 1.5% agarose
gel stained with ethidium bromide.

The four cell lines (lane 1 = Aspc1; lane 2 = Bxpc3;
lane 3 = MiaPaca2; lane 4 = PANC1) and a normal pancreatic
tissue (normal pancreas, lane 5) were analyzed by RT-PCR
15 in the above manner. The results are as shown in Fig. 2.
The results for TSA305 are shown in the upper section and
the results for β_2 -microglobulin as a control are shown in
the lower section.

From the figure, it was found that the expression of
20 TSA305 is not detected in any of cancer tissues but is
detected only in normal pancreatic tissues (cf. lane 5).

(5) Expression of the TSA305 gene in pancreatic carcinoma
(RT-PCR)

The expression of the TSA305 gene was checked in
25 pancreatic carcinoma patient-derived samples (1T, 2T, 3T,

5T, 6T, 7T, 10T and 11T), pancreatic carcinoma (Tumor Pancreas) and normal pancreas (Invitrogen; Human Normal Pancreas) as well as a cancerous portion (23T) and a noncancerous portion (23N) of the same patient by the RT-PCR technique, as follows.

mRNA was extracted from each sample and the segment of 1581-2382 bp (801 base pairs) of TSA305 was amplified by RT-PCR and tested for detecting expression or no expression. As a concentration control, β_2 -microglobulin was used. The results are shown in Fig. 3.

From the figure, reduced expression or lack of expression of the TSA305 gene was observed in all pancreatic carcinoma samples as compared with the normal pancreas.

15 INDUSTRIAL APPLICABILITY

According to the present invention, the novel pancreas-specific TSA305 gene and the protein encoded thereby are provided and, by utilizing these, a technology useful, among others, in elucidating, diagnosing, preventing and treating cancers, such as pancreatic carcinoma, or malignant transformation is provided.